Peroral Endoscopic Myotomy for the Treatment of Achalasia: An Analysis

Table 1

Clinical trials evaluating POEM for the management of achalasia.

Authors	Study design	Patients; (𝑛)	Myotomy; length; mean; (range), cm	Dysphagia score		Eckardt score		LES pressure; mean; (range), mm Hg		GERD; symptoms	Follow-up; mean (range)
				Baseline; mean	Post-POEM; mean (𝑛, %)	Baseline; mean	Post-POEM; mean (𝑛, %)	Baseline	Post-POEM
Inoue et al. [13]	Single-center; prospective	17	8.1 (3–15)	10	1.3; (17, 100%)	N/A	N/A	52.4; (14.2–80.5)	19.8; (9.3–42.7)	N/A	5 (1–16) months
Swanström et al. [14]	Single-center; prospective	5	10 (10–13)	N/A	0 or 1; (5, 100%)	N/A	N/A	36.5; (9.9– 39.8)	N/A	N/A	2 weeks
von Renteln et al. [15]	Single-center; prospective	16	12 (8–17)	N/A	N/A	N/A	≤3 (15, 94%)	27.2	11.8	None	3 months
Costamagna et al. [16]	Single-center; prospective	11	10.2 ± 2.8	N/A	N/A	7.1	1.1 (11, 100%)	45.1	16.9	None	3 months
Chiu et al. [17]	Single-center; prospective	16	10.8	2; (range 0–2)	0; (range 0-1)	5.5; (range 0–8)	0; (range 0–3); (16, 100%)	43.6 ± 24.4	29.8 ± 22	1/16; (6.25%)	176.5 (98–230) days
Hungness et al. [21]	Single-center; retrospective	18	9 (6–14)	N/A	N/A	7; (range 5–12)	1; (range 0–9); (18, 100%)	19 (7–51)	9 (0–23)	4/18 (22%) based on GerdQ score ≥7	6 (1–18) months
Zhou et al. [24]	Single-center; prospective	12	10.1 (8–13)	N/A	N/A		≤3; (11, 91.7%)	29.4; (23.5–40.2)	13.5; (8.6–22.5)	1/12 (8.3%)	10.4 (5–14) months
Verlaan et al. [18]	Single-center; prospective	10	N/A	N/A	N/A	8; (range 4–8)	1; (range 0-1); (10, 100%)	20.5; (15.8–24.3)	6.8; (4.0–12.0)	3/10 (30%)	3 months
Minami et al. [20]	Single-center; retrospective	28	14.4 (10–18)	N/A	N/A	6.7; (range 2–12)	0.7; (range 0–3); (28; 100%)	71.2; (35.8–119.0)	21.0; (6.7–41.0)	6/28 (21.4%)	16 (3–28) months
Lee et al. [19]	Single-center prospective	13	8.5 (6–13)	N/A	N/A	6.4; (range 4–10)	0.4; (range 0–2); (13; 100%)	30.3; (14.4–57.1)	15.3; (9.6–22.3)	N/A	6.9 (1–14) months
Von Renteln et al. [22]	Multicenter prospective	70	13 (5–13)	N/A	N/A		≤3; (68, 97%); at 3 months	27.6; (24.2–31.0)	8.9; (7.3–10.5)	37%	10.1 (3–12) months

N/A: not available.